10.25384/SAGE.6159617.v1 Orit Cohen-Barak Orit Cohen-Barak Sivan Weiss Sivan Weiss Michele Rasamoelisolo Michele Rasamoelisolo Nicola Faulhaber Nicola Faulhaber Paul P Yeung Paul P Yeung Pippa S Loupe Pippa S Loupe Esther Yoon Esther Yoon Mohit D Gandhi Mohit D Gandhi Ofer Spiegelstein Ofer Spiegelstein Ernesto Aycardi Ernesto Aycardi Supplementary Figure 1 bottom panel -Supplemental material for A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects SAGE Journals 2018 Calcitonin-gene-related peptide CGRP fremanezumab preventive migraine treatments TEV-48125 2018-04-18 12:00:00 Figure https://sage.figshare.com/articles/figure/Supplementary_Figure_1_bottom_panel_-Supplemental_material_for_A_phase_1_study_to_assess_the_pharmacokinetics_safety_and_tolerability_of_fremanezumab_doses_225_mg_675_mg_and_900_mg_in_Japanese_and_Caucasian_healthy_subjects/6159617 <p>Supplemental material, Supplementary Figure 1 bottom panel for A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects by Orit Cohen-Barak, Sivan Weiss, Michele Rasamoelisolo, Nicola Faulhaber, Paul P Yeung, Pippa S Loupe, Esther Yoon, Mohit D Gandhi, Ofer Spiegelstein and Ernesto Aycardi in Cephalalgia</p>